scholarly journals Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma

2017 ◽  
Vol 29 (16) ◽  
pp. 1604932 ◽  
Author(s):  
Rona Chandrawati ◽  
Jason Y. H. Chang ◽  
Ester Reina-Torres ◽  
Coline Jumeaux ◽  
Joseph M. Sherwood ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Controlled Delivery ◽  
Enzyme Biocatalysis ◽  
Outflow Pathway

scholarly journals Controlled Delivery of Nitric Oxide for Cancer Therapy

2019 ◽  
Vol 7 (4) ◽  
pp. 279-303 ◽  
Author(s):  
Houman Alimoradi ◽  
Khaled Greish ◽  
Allan B. Gamble ◽  
Gregory I. Giles
Keyword(s):  
Nitric Oxide ◽  
Cancer Biology ◽  
Tumor Targeting ◽  
Chemical Reactivity ◽  
Tumor Therapy ◽  
Multiple Roles ◽  
Controlled Delivery ◽  
Low Molecular Weight ◽  
No Donors ◽  
Potential Therapeutics

Nitric oxide (NO) is a short-lived, endogenously produced, signaling molecule which plays multiple roles in mammalian physiology. Underproduction of NO is associated with several pathological processes; hence a broad range of NO donors have emerged as potential therapeutics for cardiovascular and respiratory disorders, wound healing, the immune response to infection, and cancer. However, short half-lives, chemical reactivity, rapid systemic clearance, and cytotoxicity have hindered the clinical development of most low molecular weight NO donors. Hence, for controlled NO delivery, there has been extensive effort to design novel NO-releasing biomaterials for tumor targeting. This review covers the effects of NO in cancer biology, NO releasing moieties which can be used for NO delivery, and current advances in the design of NO releasing biomaterials focusing on their applications for tumor therapy.

A ruthenium-nitrosyl-functionalized nanoplatform for the targeting of liver cancer cells and NIR-light-controlled delivery of nitric oxide combined with photothermal therapy

2017 ◽  
Vol 5 (38) ◽  
pp. 7831-7838 ◽  
Author(s):  
Yan-Hui Li ◽  
Min Guo ◽  
Shu-Wen Shi ◽  
Qian-Ling Zhang ◽  
Shi-Ping Yang ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Liver Cancer ◽  
Cancer Cells ◽  
Photothermal Therapy ◽  
Controlled Delivery ◽  
Liver Cancer Cells ◽  
Ruthenium Nitrosyl ◽  
Nir Light ◽  
No Release

A multifunctional nanoplatform is capable of targeting liver cancer cells for NIR-light-controlled NO-release, and achieving both photodynamic and photothermal therapies.

Lipid-based carriers for controlled delivery of nitric oxide

2017 ◽  
Vol 14 (12) ◽  
pp. 1341-1353 ◽  
Author(s):  
Mahmoud A. Elnaggar ◽  
Ramesh Subbiah ◽  
Dong Keun Han ◽  
Yoon Ki Joung
Keyword(s):  
Nitric Oxide ◽  
Controlled Delivery

scholarly journals The Application of Nitric Oxide for Ocular Hypertension Treatment

Molecules ◽  
2021 ◽  
Vol 26 (23) ◽  
pp. 7306
Author(s):  
Binze Han ◽  
Maomao Song ◽  
Liping Li ◽  
Xinghuai Sun ◽  
Yuan Lei
Keyword(s):  
Nitric Oxide ◽  
Ocular Hypertension ◽  
Nitric Oxide Donors ◽  
Hypertension Treatment ◽  
Aqueous Humor Outflow ◽  
New Class ◽  
Pubmed Database ◽  
Main Pathway ◽  
Outflow Pathway ◽  
Outflow System

Despite of various therapeutic methods for treating ocular hypertension and glaucoma, it still remains the leading cause of irreversible blindness. Intraocular pressure (IOP) lowering is the most effective way to slow disease progression and prevent blindness. Among the ocular hypotensive drugs currently in use, only a couple act on the conventional outflow system, which is the main pathway for aqueous humor outflow and the major lesion site resulting in ocular hypertension. Nitric oxide (NO) is a commendable new class of glaucoma drugs that acts on the conventional outflow pathway. An increasing number of nitric oxide donors have been developed for glaucoma and ocular hypertension treatment. Here, we will review how NO lowers IOP and the types of nitric oxide donors that have been developed. And a brief analysis of the advantages and challenges associated with the application will be made. The literature used in this review is based on Pubmed database search using ‘nitric oxide’ and ‘glaucoma’ as key words.

CONTROLLED DELIVERY OF NITRIC OXIDE INHIBITS LEUKOCYTE MIGRATION AND PREVENTS VASOSPASM IN HAPTOGLOBIN 2‐2 MICE AFTER SUBARACHNOID HEMORRHAGE

Neurosurgery ◽  
2009 ◽  
Vol 65 (5) ◽  
pp. 937-945 ◽  
Author(s):  
Eric N. Momin ◽  
Kristin E. Schwab ◽  
Kaisorn L. Chaichana ◽  
Rachel Miller-Lotan ◽  
Andrew P. Levy ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Subarachnoid Hemorrhage ◽  
Controlled Delivery ◽  
Leukocyte Migration

Targeted and NIR light-controlled delivery of nitric oxide combined with a platinum(iv) prodrug for enhanced anticancer therapy

2019 ◽  
Vol 7 (11) ◽  
pp. 1867-1874 ◽  
Author(s):  
Shu-Wen Shi ◽  
Yan-Hui Li ◽  
Qian-Ling Zhang ◽  
Shi-Ping Yang ◽  
Jin-Gang Liu
Keyword(s):  
Nitric Oxide ◽  
Photothermal Therapy ◽  
Anticancer Therapy ◽  
Controlled Delivery ◽  
Light Irradiation ◽  
Nir Light

A multifunctional nanoplatform exhibits selective intracellular co-delivery of Pt(ii) and NO under 808 nm light irradiation, accompanied by photothermal therapy.

Localization of endothelial nitric oxide synthase in the normal and failing human atrial myocardium

1996 ◽  
Vol 54 ◽  
pp. 786-787
Author(s):  
Chi-Ming Wei ◽  
Margarita Bracamonte ◽  
Shi-Wen Jiang ◽  
Richard C. Daly ◽  
Christopher G.A. McGregor ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Heart Failure ◽  
Nitric Oxide Synthase ◽  
Endothelial Nitric Oxide Synthase ◽  
Cardiac Tissues ◽  
Mammalian Tissues ◽  
End Stage Heart Failure ◽  
End Stage ◽  
Oxide Synthase ◽  
Endothelial Nitric Oxide

Nitric oxide (NO) is a potent endothelium-derived relaxing factor which also may modulate cardiomyocyte inotropism and growth via increasing cGMP. While endothelial nitric oxide synthase (eNOS) isoforms have been detected in non-human mammalian tissues, expression and localization of eNOS in the normal and failing human myocardium are poorly defined. Therefore, the present study was designed to investigate eNOS in human cardiac tissues in the presence and absence of congestive heart failure (CHF).Normal and failing atrial tissue were obtained from six cardiac donors and six end-stage heart failure patients undergoing primary cardiac transplantation. ENOS protein expression and localization was investigated utilizing Western blot analysis and immunohistochemical staining with the polyclonal rabbit antibody to eNOS (Transduction Laboratories, Lexington, Kentucky).

Sign in / Sign up

Export Citation Format

Share Document